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Abstract 
Alpha-synuclein (α-syn) aggregations are the key pathological hallmark of dementia with 
Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), but are also frequently present 
in Alzheimer’s disease (AD). Yet much remains unknown about the role of α-syn in the 
synapse and the wider role of synaptic dysfunction in these dementias. Changes in 
concentrations of key ‘SNAP (Soluble N-ethylmaleimide Sensitive Factor Attachment 
Protein) Receptor’ (SNARE) proteins as a consequence of alterations in the aggregation state 
of α-syn may contribute to synaptic dysfunction in patients with DLB, PDD and AD and result 
in impaired cognition.  We have studied a large cohort (n=130) of autopsy confirmed DLB, 
PDD, AD and control brains. Using semi-quantitative western blotting we have 
demonstrated significant changes across the diagnostic groups of DLB, PDD and AD in the 
SNARE and vesicle proteins syntaxin, Munc18, VAMP2 and monomeric α-syn in the 
prefrontal cortex, with a significant reduction of Munc18 in AD patients (p<0.001). This 
correlated to the final MMSE score before death (p=0.016). We also identified a significant 
negative correlation between the duration of dementia and the levels of the binding 
partners VAMP2 (p=0.0004) and monomeric α-syn (p=0.0002). It is of particular note that this 
association was identified in people with AD. Our findings may indicate that an upregulation 
of SNARE complex related proteins occurs in the early stages of disease as an attempt at 
compensating for failing synapses, prior to widespread deposition of pathological α-syn.  
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Abbreviations 
AD – Alzheimer’s disease, LBD – Lewy body dementias, DLB – dementia with Lewy bodies, 
PDD – Parkinson’s disease dementia, SPP – synaptophysin, VAMP2 – vesicle-associated 
membrane protein 2, SNARE - SNAP (Soluble N-ethylmaleimide Sensitive Factor Attachment 
Protein) Receptor, α-syn – alpha-synuclein, Aβ – amyloid-β protein, MMSE – mini mental-state 
examination, LB(s) – Lewy body(ies).  
Introduction 
Dementia is defined as progressive cognitive decline of sufficient magnitude to interfere with normal 
social or occupational function. Alzheimer’s disease (AD) and the Lewy body dementias (LBD), 
incorporating dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), collectively 
comprise over 70% of all dementia diagnoses (www.alzheimers.org.uk).  LBD is pathologically 
characterized by α-synuclein (α-syn), with varying amounts of amyloid-β protein (Aβ) and 
hyperphosphorylated microtubule associated protein tau  (tau) aggregates in addition to synaptic 
loss (Dickson, 2002). Clinical hallmarks include fluctuating and deteriorating cognition, 
hallucinations, and parkinsonism (McKeith et al., 2005; Aarsland et al., 2008). AD is characterised by 
Aβ and tau aggregates and gradual worsening of cognition – in particular episodic memory and 
executive function (Ballard et al., 2011; McKhann et al., 2011). 
α-Syn, first identified as the main component of Lewy bodies (LBs) (Spillantini et al., 1997) – 
and thus the key pathological protein of DLB and PDD - is, under physiological conditions, 
located in the presynaptic terminal. Kramer and Schulz-Schaeffer (Kramer and Schulz-
Schaeffer, 2007) reported accumulation of small aggregates of α-syn at the synapses of DLB 
post mortem brains. These aggregates were proposed to interfere with synaptic function. 
The authors also suggested that the formation of small aggregates of α-syn was a direct 
precursor to the development of LBs, and possibly represented a final cytoprotective 
attempt before cell death. Thus, focus on the events occurring at the synapse in advance of 
LB formation could be of greater potential therapeutic benefit. This is of relevance not just 
to the established synucleinopathies such as DLB and PDD but also AD. It is now recognised 
that a proportion of sporadic AD cases present with Lewy bodies; this has been reported to 
be as high as 51% (Jellinger, 2003), and is particularly observed within the amygdala where 
Lewy bodies are often co-localised with neurofibrillary tangles (Schmidt et al., 1996; 
Uchikado et al., 2006; Fujishiro et al., 2008). 
Some of the mutations in the SNCA gene known to give rise to α-syn disorders exert their 
pathogenic effect through promotion of aggregation or oligomerisation of α-syn (Brown, 
2010). In addition to  involvement in pathogenic mechanisms there has been increasing 
focus on the physiological role of α-syn. Current understanding indicates that α-syn plays a 
role in neurotransmitter release, synaptic plasticity and pre-synaptic vesicle pool size 
(Abeliovich et al., 2000; Murphy et al., 2000; Lee et al., 2014). More particularly it is thought 
that monomeric α-syn drives formation of the SNARE complex through a chaperone-like 
activity involving binding to phospholipids and VAMP2 (vesicle-associated membrane 
protein 2 – or synaptobrevin-2) (Burré et al., 2010). SNARE is an acronym for ‘SNAP (Soluble 
N-ethylmaleimide Sensitive Factor Attachment Protein) Receptor’. SNARE proteins play a 
key role in neurotransmitter-containing vesicle fusion to the presynaptic membrane thereby 
modulating neurotransmitter release (Jahn and Fasshauer, 2012). Interestingly, it was 
recently reported that large α-syn oligomers bind preferentially to VAMP2 (vesicle-
associated membrane protein 2), resulting in inhibition of docking between donor and 
acceptor vesicles (Choi et al., 2013). Thus it is plausible that VAMP2 could represent a key 
component for mediating the impact of α-syn. 
VAMP2 and syntaxin 1, both members of the SNARE protein family, are respectively 
localised to synaptic vesicles and the presynaptic membrane where they form part of the 
SNARE complex required for vesicle release (Jahn and Fasshauer, 2012). Munc18 binds to 
syntaxin 1, and is thought to assist in the first steps of SNARE assembly, as well as playing a 
role in later stages of the exocytosis (Jacobs et al., 2006; Han et al., 2010; Jorgacevski et al., 
2011). Reductions in SNARE proteins have been previously reported in LBD and AD 
(Mukaetova-Ladinska et al., 2009; Mukaetova-Ladinska et al., 2013). This study aims to aid 
our understanding of the synaptic dysfunctions that may underlie the disease process 
observed throughout the development of LBD and AD. Our hypothesis was that changes in 
concentrations of key SNARE proteins as a consequence of alterations in the aggregation 
state of α-syn may contribute to synaptic dysfunction in people with LBD and AD and result 
in impaired cognition.  We therefore determined the expression of the presynaptic proteins 
α-syn, VAMP2, syntaxin1A, Munc18, and the general synaptic marker synaptophysin (SPP) 
and investigated the potential correlations between these proteins and clinical data. 
 
  
Materials and Methods 
Participants, diagnosis and assessment 
Table 1 shows the demographic details of the patients and controls. Post-mortem brain 
tissue was kindly supplied by the following Brains for Dementia Research Network brain 
banks: the MRC London Neurodegenerative Diseases Brain Bank, the Thomas Willis Oxford 
Brain Collection and the Newcastle Brain Tissue Resource, and from the University Hospital 
Stavanger (Norway). Informed consent was obtained for all tissue to be used in research and 
the study had ethics approval (08/H1010/4). Prefrontal cortex (Brodmann area, BA9) was 
used for all biochemical and histopathological analysis. BA9 was selected due to its 
proposed role in executive function and cognition (Fuster, 2001), decline of which is a 
cardinal symptom of DLB and PDD,  
Neuropathological assessment was performed according to standardised neuropathological 
scoring/ grading systems, including Braak staging, Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) scores, Newcastle/ McKeith Criteria for Lewy body disease, 
National Institute on Aging - Alzheimer’s Association (NIA-AA) guidelines and phases of 
amyloid-β (Aβ) deposition (Aβ-phases) (Mirra et al., 1991; Thal et al., 2002; McKeith et al., 
2005; Braak et al., 2006; Montine et al., 2012). Controls were neurologically normal, with 
only mild age associated neuropathological changes (e.g., neurofibrillary tangle Braak stage 
≤II) and no history of neurological or psychiatric disease.  
Cognitive impairment data consisted of the last Mini-Mental State Examination (MMSE) 
scores a maximum of two years prior to death (Folstein et al., 1975). Patients and controls 
were categorised as previously described (Whitfield et al., 2014b). Final diagnoses for 
patients are clinico-pathological consensus diagnoses incorporating the one-year rule to 
differentiate DLB and PDD (McKeith et al., 2005). 
  
Immunohistochemistry 
Semi-quantitative assessments of Aβ, tau and α-syn pathology were conducted as in our 
previous study (Howlett et al., 2014) blind to clinical diagnosis, by neuropathologists, using a 
scale of 0 (none), 1 (sparse), 2 (moderate) and 3 (severe/frequent) to score sections from 
BA9, BA24 and BA40. For detection of senile Aβ plaques sections were stained with an anti-
Aβ 1E8 or 4G8 antibody at 1:1000. Tau immunohistochemistry (AT8 antibody (Innogenetics) 
at 1:200) and silver impregnation (Gallyas or modified Bielschowsky) were used to detect 
neurofibrillary tangles, neuritic plaques, dystrophic neurites and neuropil threads. α-syn 
pathology was detected using NCL-SYN antibody (Novocastra Laboratories) at 1:200. 
 
Preparation of tissue samples for western blotting 
Preparation of tissue for western blotting was as previously described (Kirvell et al., 2006). 
Briefly, grey matter was isolated from the tissue and homogenised in ice cold buffer 
containing 50mM tris-HCL, 5mM EGTA, 10mM EDTA, ‘complete protease inhibitor cocktail 
tablets’ (Roche, 1 tablet per 50ml of buffer), and 2μg/ml pepstatin A dissolved in 
ethanol:DMSO 2:1 (Sigma). Buffer was used at a ratio of 2ml to every 100mg of tissue and 
homogenisation performed using an IKA Ultra-Turrax mechanical probe (KIA Werke, 
Germany) until the liquid appeared homogenous. 
Protein concentration was established using the Coomassie (Bradford) Protein Assay Kit 
(Thermo Scientific); 10μl of crude homogenate was diluted 1:50 and read in triplicate at 
595nm using a FlexStation 3 (Molecular Devices). A BSA standard curve run at the same time 
as the samples was used to calculate the concentration. 
 
Western Blotting 
Crude brain homogenate was diluted 4:5 with 5x sample buffer (Genscript MB01015), boiled 
for 5 minutes then stored at -20°C. Samples were loaded at 20μg/ml total protein on 10% 
SDS-polyacrylamide gel for protein separation, transferred to nitrocellulose membrane 
(Hydrobond-C, Amersham) and probed with either anti-Syntaxin1 (abcam ab24731, 
1:20000), anti-Munc18 (abcam ab75042, 1:2000), anti-VAMP2 (abcam ab70222, 1:10000), 
anti-alpha-synuclein monomeric (BD Transduction Laboratories 610787, 1:20000) or anti-
synaptophysin (abcam ab8049, 1:10000) and the relevant secondary antibody (IRDye from 
LI-COR). Bands were detected using an Odyssey infrared fluorescent scanner, the integral of 
intensity quantified using Odyssey infrared imaging systems application software version 
3.0.16 and expressed as ratios to rat cortex in arbitrary units.     
Statistical Analysis 
Statistical analysis of the biochemical data was undertaken as described previously 
(Whitfield et al., 2014a; Whitfield et al., 2014b); briefly synaptophysin values were 
significantly predicted by the years in storage and so a residual variable was created for this 
protein to statistically remove this effect. This variable was then normalised using a log10 
transformation. Munc18 and VAMP2 ratio values were normalised using a square root 
transformation. Syntaxin1 and monomeric α-syn ratio values were normalised using a LogE 
transformation. VAMP2 and monomeric α-syn ratio values were significantly predicted by 
age at death and so residual variables were created to compensate for this effect. VAMP2 
ratio values were then normalised again using LogE. 
 
  
Results 
Synaptophysin (SPP) levels were significantly reduced in PDD cases compared to all other 
diagnostic groups but there was no significant difference between the levels of 
synaptophysin in control, AD or DLB cases (supplementary figure 1). As Munc18, syntaxin1, 
VAMP2 and monomeric α-syn are all synaptic proteins and we observed the 
aforementioned decrease in synapses, it was decided to express these proteins as ratios to 
the synaptophysin value, case by case. This established approach allows the actual change in 
these proteins to be removed from any general effect of a change in synapses (Weiler et al., 
1990; Vawter et al., 1999).  
In the Munc18:synaptophysin ratio, there was a reduction in AD cases of 33%  compared to 
DLB cases, 26% compared to PDD and 25% compared to control cases (Fig. 1A). The 
significant changes in the syntaxin1:synaptophysin ratio were an increase of 28% in AD cases 
compared to PDD cases and 34% compared to control cases (Fig. 1B). The ratio of VAMP2 to 
synaptophysin was significantly higher in PDD cases compared to controls by 16%, to DLB 
cases by 23%, and to AD cases by 65%. Furthermore, the ratio of VAMP2 to synaptophysin 
was significantly lower in AD cases compared to DLB cases by 34% and compared to 
controls, by 42% (Fig. 1C). The ratio of monomeric α-syn to synaptophysin was significantly 
higher in PDD cases compared to controls, by 25% and to AD cases by 53%. Furthermore it 
was significantly lower in AD cases compared to DLB cases by 38% and compared to 
controls, by 22% (Fig. 1D).  
Linear regression analysis showed the years of dementia to have a highly significant 
negative correlation with the ratios of VAMP2 to synaptophysin (figure 2A) and monomeric 
alpha-synuclein to synaptophysin (figure 3A) in the prefrontal cortex. Likewise, a significant 
positive correlation was found between years of parkinsonism and both the ratio of VAMP2 
to synaptophysin (figure 2B) and the ratio of monomeric a-syn to synaptophysin (figure 3B) 
in the prefrontal cortex. Both of these analyses included all individuals with AD, DLB and 
PDD, for whom data on the duration of dementia was available, but not controls. The n 
values for years of dementia for both VAMP2:SPP and α-syn:SPP were; PDD n=18, DLB=23 
and AD=15. For years of parkinsonism they were; PDD n=18, DLB n=20 and AD n=15. 
The ratio of Munc18 to synaptophysin correlated with the last MMSE score prior to death 
(Pearson’s r=0.282, p=0.016, n=73); the distribution and other details of the MMSE scores 
for this cohort have been reported previously (Whitfield et al., 2014b). There was no 
correlation between MMSE scores (the last score prior to death or the decline per year) and 
any of the other protein ratios (p>0.05). There was also no correlation between any of the 
protein ratios and the semi-quantitative pathology scores for Aβ, tau or α-syn (p>0.05).  
Discussion 
We report that a longer duration of dementia was strongly association with a decrease in 
levels of both VAMP2 and monomeric α-syn. Furthermore VAMP2 and monomeric α-syn 
appeared to be upregulated in PDD cases; cases that in general had low levels of α-syn 
pathology compared to the DLB cases (see figure 4). This may indicate that an upregulation 
of SNARE process related proteins occurs in the early stages of dementia as an attempt to 
compensate for failing synapses, prior to widespread deposition of pathological α-syn. 
α-syn aggregation is the pathological hallmark of DLB and PDD, appearing as Lewy bodies 
and neurites throughout the cortex, but is also present in a significant proportion of people 
with AD. Whilst evidence is emerging of the physiological roles of monomeric α-syn in 
SNARE complex processes, less is known about the intermediate steps that lie between this 
physiological role and the final pathological deposition seen in the end-stages of disease. 
We saw a strikingly similar pattern of change between VAMP2 and monomeric alpha-
synuclein, which is not surprising given that the two proteins are binding partners (Burré et 
al., 2010). 
A benefit of expressing the biochemical data as a ratio to synaptophysin is that this provides 
an index to the number of synaptic terminals, and importantly the results were not 
substantially different when this ratio was not used (data not shown). 
The accumulation of α-syn and SNARE proteins at synaptic nerve terminals in transgenic 
mice and in Parkinson’s disease, in conjunction with impaired dopamine release in both 
transgenic mouse brain and transfected PC12 cells, is suggested by Garci-Reitbbock and 
colleagues to indicate a gain of toxic function of α-syn at the synapse (Garcia-Reitbock et al., 
2010). This is consistent with previous findings in transfected cells, which showed that 
overexpression of α-syn inhibits evoked neurotransmitter release by acting at a step 
between vesicle docking and fusion (Larsen et al., 2006). It could be that a balance between 
monomeric α-syn and SNARE proteins is necessary for proper SNARE assembly and function; 
alternatively, it could be that an increase in α-syn causes the formation of toxic oligomers 
that affect SNARE distribution and function. This causes a problem as an oligomer of α-syn 
can bind to many VAMP2 proteins on several different vesicles causing vesicle clustering 
(Choi et al., 2013). By clustering around oligomeric α-syn, vesicles cannot dock at the pre-
synaptic terminal and therefore exocytosis of neurotransmitter cannot occur. 
Here we observed a combination of increases in both monomeric α-syn and VAMP2 in PDD 
cases. A recent study reported increased expression of VAMP2 protein accompanied 
increased α-syn expression in the striatum of Snap25S187A/S187A mice (Nakata et al., 
2012). These mice displayed a significant age-dependent change in the distribution of α-syn 
and its Ser129-phosphorylated form in hypertrophied glutamatergic nerve terminals in the 
striatum. Knowing that the binding of the C terminus of α-syn to the N terminus of VAMP2 
primes the subsequent SNARE complex assembly (Burgoyne and Morgan, 2011), the 
increase in VAMP2 level might also reflect a compensatory response to the impaired 
synaptic vesicle release by enhancing SNARE complex formation in concert with the 
increased α-syn (Nakata et al., 2012). This increase in VAMP2 and monomeric α-syn could 
also relate to the inherent differences between PDD and the other dementias, such as the 
typically long period of parkinsonism prior to development of dementia, or to the relative 
lack of AD related pathology. 
The positive correlation between MMSE prior to death and the ratio of Munc18 to 
synaptophysin underlines the importance of intact synaptic machinery to cognition. That we 
did not see correlations with the other proteins is probably due to the prefrontal cortex not 
being a key region for memory – having a stronger role in executive function, a domain 
which the MMSE is poor at detecting (McKeith et al., 2005). We have previously shown that 
α-syn pathology in BA21 is associated with cognitive decline as assessed by the MMSE 
(Howlett et al., 2014), and so it would be interesting to examine these SNARE proteins in 
this region to determine if monomeric α-syn shows a similar relationship to pathological α-
syn. 
In the present study, we found that a concomitant deregulation of SNARE proteins and 
monomeric α-syn was strongly associated with the duration of dementia. It has been 
suggested that this process could represent an initial pathological event in DLB, eventually 
leading to the death and degeneration of neuronal cells (Orimo et al., 2008). Alterations in 
syntaxin and other SNARE proteins have been previously reported in AD and DLB (Minger et 
al., 2001; Jacobs et al., 2006; Mukaetova-Ladinska et al., 2009; Mukaetova-Ladinska et al., 
2013); Minger et al only found a decrease in these proteins in the oldest dementia cases and 
the Mukaetova-Ladinska studies did not separate PDD and DLB. The toxicity of α-syn, in 
sporadic and familial disease, has been proposed to arise in several ways; through inhibition 
of histone acetylation, perforation of membranes and the consequent disruption of ionic 
balance and finally neuronal death via the inhibition of a neuronal survival factor MEF2D 
(Beyer et al., 2009). Beyer et al suggest that in fact there maybe multiple pathways involving 
α-syn and other proteins linked to LBs that culminate in the same end-stage pathology of 
Lewy bodies and neurites.  
Targeting the toxicity of α-syn at the synapse, and its connection with SNARE proteins, could 
be an effective way to tackle the pathology and the progression of the disease at an early 
stage. Further functional studies are warranted to provide insight into the chronology of the 
relationship between VAMP2 and monomeric α-syn: are changes in VAMP2 driving a loss of 
monomeric α-syn to other forms of α-syn? Or is the loss of monomeric α-syn impacting 
VAMP2, SNARE machinery and ultimately synaptic function? Finally, development of 
imaging ligands or an assay for CSF detection of VAMP2 or monomeric α-syn would be of 
great interest given the predictive association we show between duration of dementia and 
parkinsonism, and these proteins.  
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CONTROL DLB PDD AD 
Number of 
cases 
24 50 33 16 
Age of death 80.4 ± 1.4 81.7 ± 1.0 79.8 ± 1.1 88.0  ± 2.0 
PMD (hours) 37.1 ± 6.4 42.9 ± 4.1 33.4 ± 2.9 34.9 ± 6.0 
Gender M/F (%) 58 / 42 56 / 44 53 / 47 31 / 69 
Brain pH 6.47 ± 0.07 6.52 ± 0.04 6.47 ± 0.06 6.30 ± 0.08 
 
Table 1: Summary of subjects demographics 
Values represent means ± SEM.  There were no significant differences (according to one-way 
ANOVA) between diagnostic groups for any of these variables. It has been demonstrated that most 
human brain proteins are quite stable with respect to post-mortem factors and detailed analysis 
including large numbers of proteins covering the major cellular functions have not identified our 
proteins of interest as ‘at risk’ molecules being highly susceptible to post-mortem changes (Lewis, 
2002; Hynd et al., 2003; Crecelius et al., 2008; Ferrer et al., 2008).  
 
 
 
 
 
 
 
 
 
Figure 1 
 
Figure 1: Synaptic proteins of interest expressed as a ratio to synaptophysin (SPP) and grouped 
according to clinical diagnosis. 
One-way ANOVA and Bonferroni post-hoc tests were used to determine the differences in the 
protein ratios between diagnostic groups. 
Graph A: Munc18; n=23,30,37,16. F=(3,102)11.995, p=0.000001. Bonferroni post-hoc tests showed  
AD cases to be significantly higher than; control p=0.001 ,PDD p=0.000273 and DLB p<0.000001. 
Graph B: Syntaxin1; n=23,31,37,16. F(3,103)5.128, p=0.002. Bonferroni  post-hoc tests showed AD 
cases to be significantly lower than control p=0.007 and PDD p=0.017. 
Graph C: VAMP2; n=19,24,29,15. F=(3,83)25.814, p<0.000001. Bonferroni post-hoc tests showed; 
PDD cases to be significantly higher than; control p=0.01, DLB p=0.000019 and AD cases p<0.000001. 
Furthermore AD cases were significantly lower than control p=0.000004 and DLB cases p=0.000073. 
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Graph D: Mon α-syn; n=19,24,28,15. F(3,82)16.621, p<0.000001. Bonferroni PDD to control 
p=0.000463. AD to; control p=0.049, PDD p<0.000001, DLB p=0.000027. The vertical bars represent 
means with SEM.  
  
Figure 2: Associations between the monomeric α-synuclein:synaptophysin (α-syn/SPP) ratio and the 
duration of dementia and parkinsonism.  
 
 
 
Linear Regression analysis showed the years of dementia and of parkinsonism to be predictors of the 
ratio of monomeric α-syn to SPP in BA9. R2=0.399. SE= 0.371664. Years of dementia; B=-0.06, 
SE=0.015, t=-4.034, p= 0.000188. Years of PD; B=0.21, SE=0.008, t=2.801, p=0.007. ANOVA; 
F=(2,50)16.599, p= 0.000003.   
Figure 3: Associations between the VAMP2:synaptophysin ratio and the duration of dementia and 
parkinsonism. 
 
 
 
Linear Regression analysis showed the years of dementia and of parkinsonism to be predictors of the 
ratio of VAMP2 to SPP. R2=0.463. SE= 0.17939. Years of dementia; B=-0.028, SE=0.007, t=-3.833, p= 
0.000355. Years of PD; B=0.15, SE=0.004, t=4.032, p= 0.000189. ANOVA; F=(2,50)21.595, p< 
0.000001.   
Figure 4: α-synuclein pathology grouped by clinical diagnosis. 
 
The percentage of cases in each of the categories of α-synuclein pathology score (0 = absent, 1 = 
sparse, 2 = moderate, 3 = severe/frequent) according to clinical diagnosis. 
 
